Table 2.

Association between cIAP2-positive immunostaining in lung tumors and tumor response to cisplatin-based chemotherapy in these patients with tumor recurrence and/or metastasis after surgical resection

cIAP2Total NTumor responseP
FavorablePoor
n (%)n (%)
Negative1810 (56)8 (44)0.036
Positive287 (25)21 (75)

NOTE: One hundred and one of the 136 patients enrolled in this study were followed up clinically. Among these patients, 63 patients were found to have tumor recurrence and/or metastasis after surgical therapy, and 46 patients were treated with cisplatin-based chemotherapy. Complete response: a complete disappearance of all the tumors; partial response: a decrease in size or number of the tumor lesions by ≥50%; progressive disease: at least 25% increase in size or number of the tumor lesions; stable disease: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Therefore, the favorable response (complete and partial response) is the decrease of tumor size at least ≥50%. P value was calculated by χ2 test.